Access of People Living with HIV to Testing Services in Greece: A Challenge for Equity in Care

Kyriakos Souliotis 1,2,*, George Tsiakalakis 1, Christina Golna 2, Dimitra Sifaki-Pistolla 2, Nikos Dedes 3 and Marios Lazanas 4

1 Faculty of Social and Education Sciences, University of Peloponnese, 20100 Corinth, Greece
2 Health Policy Institute, 15123 Athens, Greece
3 Greek Association of People Living with HIV Positive Voice, 10554 Athens, Greece
4 Internal Medicine and Infectious Diseases Department of IASO General Clinic, Hellenic Society for the Study and Control of AIDS (EEMAA), 15123 Athens, Greece
* Correspondence: ksouliotis@uop.gr

Abstract: (1) Background: Access to laboratory testing services for HIV in Greece is persistently challenged and this impacts both the continuum of care and, potentially, equity in access. (2) Methods: A cross-sectional study with two parts (first part: HIV-positive people/PLWHIV; second part: HIV clinicians) was conducted in Greece to quantify challenges regarding access to laboratory testing for HIV. Data were collected through online surveys, during a one-month period, between 2019 and 2020. The total sample consisted of 153 PLWHIV and 26 HIV clinicians. (3) Results: Access to viral load testing varied significantly according to place of residence (p = 0.029) and year of diagnosis (p = 0.054). Patients diagnosed after 2015 reported worse access to viral load testing (72.7% vs. 85.9%). Over one third of respondents perceived viral load tests as being not at all accessible (11.4%) or somewhat accessible, only after facing multiple systemic obstacles (24.2%). Equally, most of HIV clinicians reported barriers or no access to baseline viral load testing (80%) and baseline genotype resistance tests (96%). (4) Conclusions: Access of people diagnosed with HIV to CD4 lymphocyte tests and genotype resistance screening is significantly challenged in Greece, especially after 2015. Addressing this challenge is critical in removing access barriers and achieving the UNAIDS 95-95-95 HIV elimination goals.

Keywords: HIV; HIV testing; lymphocyte tests; genotype resistance; accessibility; continuity

1. Introduction

Scientific advances in HIV treatment over the last 25 years have transformed the condition into a chronic one and provided patients with a satisfactory quality of life [1]. The Joint United Nations Programme on HIV/AIDS (UNAIDS) in its latest HIV Strategy [2] calls for bold elimination goals that include at least 95% of people living with HIV (PLWHIV) knowing their status, 95% of those being linked to appropriate care and receiving antiretroviral treatment (ART) and 95% of the latter being virally suppressed. To achieve these bold goals the strategy “keeps PLWHIV at its center to ensure that they benefit from optimal standards in service planning and delivery, to remove social and structural barriers that prevent them from accessing HIV services, to empower communities to lead the way, to strengthen and adapt systems so they work for the people who are most acutely affected by inequalities, and to fully mobilize the resources needed to end AIDS” [2].

Such priorities are clearly aimed to address inequalities in access to care that may be formed or affected by disparities and inefficiencies in care delivery as well as health services and community stigma [3]. Irrespective of source of such inequalities, their impact on equity in access is undeniable [3,4]. Failure to ensure equity in access to HIV diagnosis and care is doubly critical in terms of both individual and public health outcomes, as late diagnosis and not achieving swift viral suppression exposes the person living with HIV...
to disease progression and complications and the community to potentially additional infections [5].

In Greece, HIV management has traditionally been considered a well-managed area of health care and a paradigm for efficient use of healthcare resources [6]. Systematic epidemiological surveillance by the National Public Health Organization (EODY), a comprehensive registry for PLWHIV under care, which records any treatment regimens dispensed [7], coupled with physician’s freedom in treatment choice according to individualized conditions, and patient management by Infection Disease Units (IDUs) and HIV Clinics within the NHS, have contributed to this efficient disease management. Nonetheless, it seems that there remain significant challenges with access to HIV diagnostic tests, baseline screening, and laboratory monitoring services [7]. Such services have until very recently been reserved for public laboratories only, with reagents tendered centrally through the National Retroviral Reference Center (EKAR), whereas access to reimbursed testing services in the private sector has only recently been introduced, with significant challenges remaining as regards the safeguarding of anonymity and confidentiality of data of PLWHIV. Meanwhile, delays in central tenders by EKAR have repeatedly challenged access to services even within the NHS.

As a result, it has been increasingly difficult to follow both Greek [8,9] and European [10] guidelines in clinical practice. Both recommend that CD4 lymphocyte and viral load screening be performed at least twice a year. Genotype resistance testing is recommended before starting the first ART regimen, ideally at the time of diagnosis or in case of a superinfection [8–10]. Delays in performing such testing may impact on rapid initiation of treatment or treatment optimization and as such they generate inequities for PLWHIV, jeopardize universal access to laboratory tests, and may have major implications for epidemiological surveillance and, ultimately, public health [9,10]. Lastly, it should be noted that there are Greek studies highlighting the increased unmet health needs of HIV positive people, especially during and after the era of the financial crisis [7]. These needs had to be managed with decreasing available funds, which might have impacted the access to and quality of offered services [11].

This study reports on challenges related to accessing laboratory testing services for HIV in Greece (CD4 lymphocytes, viral load, genotype resistance) to quantify its potential impact on the continuum of care that affects both individual and public health outcomes, as well as equity in access to health care services overall.

2. Materials and Methods

2.1. Study Design

The present research is a cross-sectional study with two parts. The first part was addressed to PLWHIV and the second part was addressed to HIV clinicians employed in Infectious Disease Units of the National Health System (NHS) across the country. Data were collected through online surveys, one for each part of the survey, during a one-month period, between 10 December 2019, and 10 January 2020. Geographical regions are reported using three categories (i.e., Attica, Thessaloniki and rest of Greece). Attica is the capital region of Greece, representing the biggest, highest populated urban city. Thessaloniki is the second biggest city of medium density, while rest of Greece is comprised of semi-urban and rural cities and villages. The categorization in three major regions is performed in line with the concentration of PLWHIV in treatment centers for care, with the vast majority in Athens [12].

2.2. Study Population and Procedures

Study sample consisted of 153 PLWHIV, who were members of the HIV Patient Organization “Positive Voice”, as well as 26 HIV clinicians employed in the 20 Infectious Disease Units & HIV Outpatient Clinics of the National Health System (NHS), who were members of the Hellenic Society for the Study and Control of AIDS (EEMAA).
Purposive sampling (non-probabilistic approach) was used to select study sample, as both PLWHIV and HIV clinicians are considered special groups to identify for the needs of a random or other probabilistic sampling. An email was sent separately to the Boards of Directors of both Positive Voice and EEMAA along with the study’s protocol and instrument for approval. Both agreed to participate in the study and sent a participation invitation, an informed consent form, information regarding the study and a link to each respective questionnaire to its members. All recipients had the same chance of participating in the study.

According to the National Organization for Public Health (EODY) [13], in 2021, there were 526 new HIV diagnoses and approximately 17,113 people diagnosed and living with the condition in Greece, of which 10,618 were on Anti Retroviral Treatment (ART) on 31 December 2019 [14].

2.3. Research Tool

The questionnaire addressed to patients included questions on the socio-demographic characteristics of participants (gender, age, educational level, and place of residence), on the disease (time of diagnosis, time on treatment, treatment optimization) and questions regarding the accessibility and availability of laboratory testing during diagnosis, baseline screening and regular monitoring. Respondents were also asked if they were aware of their current HIV status (viral load detectable or not).

The questionnaire addressed to HIV physicians included questions on the socio-demographic characteristics of participants (gender, age, years of experience, and place of employment) and questions regarding the accessibility and availability of laboratory tests for their patients - PLWHIV.

2.4. Pilot Study

We conducted a pilot study to evaluate the effectiveness of the survey questionnaire in answering the research question amongst the first group (PLWHIV). The questionnaire was pre-tested with two representatives of “Positive Voice” to ensure validity, clarity in language, and ability to be clearly understood by respondents. Feedback from the pilot study was incorporated into the final questionnaire. Responses provided during the pilot were excluded from the final sample and analysis.

2.5. Statistical Analysis

All p-values reported are two-tailed. Statistical significance was set at 0.05 and analyses were conducted using SPSS statistical software (IBM, New York, USA, version 24.0). Chi-square and Fisher’s exact tests were used to compare the observed proportions.

3. Results

Table 1 presents sample sociodemographic characteristics both for PLWHIV (n = 154) and HIV specialists (n = 26). PLWHIV who participated in the survey were diagnosed on average 9.21 years ago (SD = 6.63, range from 0 to 34 years) and had been receiving antiretroviral treatment for an average of 7.64 (SD = 5.95) years.

Most participants stated that baseline CD4 testing was quite (39.5%) or very (47.4%) accessible; however, over 1 in 10 considered it either not accessible at all (4.6%) or accessible only after overcoming a series of systemic obstacles (8.6%). 73.9% stated that they underwent a viral load test (HIV RNA) within 2 weeks of diagnosis, while 17.6% did not.

Access to viral load testing varied significantly according to place of residence ($\chi^2$ (1140) = 4778 $p = 0.029$) and year of diagnosis ($\chi^2$ (1140) = 3712, $p = 0.054$). Patients diagnosed after 2015 stated worse access to viral load testing compared to those diagnosed before 2015 (72.7% vs. 85.9%, respectively). Regarding place of residence, patients who lived outside of Athens (69.8%) were also less able to undergo viral load testing compared to residents of Athens (85.6%) (Table 2).
Table 1. Socio-demographic characteristics of the sample.

|                     | PLWHIV | HIV clinicians |
|---------------------|--------|----------------|
| **Gender**          |        |                |
| Man                 | 150 (98.0%) | 14 (53.8%)    |
| Woman               | 3 (2.0%)   | 12 (46.2%)    |
| **Age**             |        |                |
| 18–24               | 4 (2.6%)   |                |
| 25–34               | 31 (20.3%)  |                |
| 35–44               | 54 (35.3%)  |                |
| 45–54               | 49 (32.0%)  |                |
| 55–64               | 13 (8.5%)   |                |
| 65+                 | 2 (1.3%)    |                |
| **Educational level** |      |                |
| Compulsory education| 5 (3.3%)    |                |
| Secondary education | 36 (23.5%)  |                |
| Tertiary education  | 75 (49.0%)  |                |
| Master’s degree/PhD | 37 (24.2%)  |                |
| **Place of residence** |      |                |
| Attica              | 109 (71.2%) | 23 (88.5%)    |
| Thessaloniki        | 24 (15.7%)  | 1 (3.8%)      |
| Rest of Greece      | 20 (13.1%)  |                |
Table 2. Baseline Screening for CD4 lymphocytes and viral load (HIV RNA), within 2 weeks of diagnosis.

| Within 2 weeks of your diagnosis, did you undergo a CD4 lymphocyte test? |
|---|
| No | 15 (9.8%) |
| Yes | 125 (81.7%) |
| I don’t remember | 13 (8.5%) |

| If yes, did you receive the results of your test within 2 weeks? |
|---|
| No | 6 (4.2%) |
| Yes | 130 (90.3%) |
| I don’t remember | 8 (5.6%) |

| How accessible/available was this test to you (2 weeks after diagnosis)? |
|---|
| Not at all | 7 (4.6%) |
| Somewhat (after facing many systemic obstacles) | 13 (8.6%) |
| Fairly | 60 (39.5%) |
| Very much | 72 (47.4%) |

| Within 2 weeks of your diagnosis, did you undergo a viral load test (HIV RNA)? |
|---|
| No | 27 (17.6%) |
| Yes | 113 (73.9%) |
| I don’t remember | 13 (8.5%) |

| If yes, did you receive the results of your test within 2 weeks? |
|---|
| No | 26 (17.9%) |
| Yes | 106 (73.1%) |
| I don’t remember | 13 (9.0%) |

| How accessible/available was this test to you (2 weeks after diagnosis)? |
|---|
| Not at all | 24 (15.8%) |
| Somewhat (after facing many systemic obstacles) | 16 (10.5%) |
| Fairly | 47 (30.9%) |
| Very much | 65 (42.8%) |

Regarding their most recent monitoring tests, 30.7% of respondents reported not receiving their latest CD4 lymphocyte test results and 50% reported not receiving their most recent viral load (HIV RNA) test results within 2 weeks. There was no statistically significant difference between patients’ place of residence (CD4: $\chi^2 (1.142) = 0.663$, $p = 0.416$ and Viral load: $\chi^2 (1.138) = 1.370$, $p = 0.242$, respectively) or the year of diagnosis (CD4: $\chi^2 (1.140) = 0.149$, $p = 0.699$ and Viral load: $\chi^2 (1.136) = 1.025$, $p = 0.311$) and acquiring or not results of monitoring tests within 2 weeks (Table 3).

In addition, 35.3% of the PLWHIV sample reported visiting a private laboratory for a viral load test in the last 12 months. There was no statistical difference between this choice and place of residence ($\chi^2 (1.152) = 0.421$, $p = 0.517$) or year of diagnosis ($\chi^2 (1.150) = 1.487$, $p = 0.223$). At the time of the study, over one-third of respondents perceived viral load tests as being not all accessible (11.4%) or somewhat accessible, only after facing multiple systemic obstacles (24.2%) (Table 3).
Table 3. Patient responses on most recent testing results.

| Did you receive the results of your CD4 lymphocyte test within 2 weeks? |  |
|---|---|
| No | 46 (30.7%) |
| Yes | 96 (64.0%) |
| I don’t remember | 8 (5.3%) |

| Did you receive the results of your HIV RNA test within 2 weeks? |  |
|---|---|
| No | 74 (50.0%) |
| Yes | 64 (43.2%) |
| I don’t remember | 10 (6.8%) |

| Did you undergo a viral load test in a private lab within the last 12 months? |  |
|---|---|
| No | 98 (61.4) |
| Yes | 54 (35.3) |
| I don’t remember | 1 (0.7) |

| At this time, how accessible/available would you describe viral load testing to you? |  |
|---|---|
| Not at all | 17 (11.4%) |
| Somewhat (after facing many systemic obstacles) | 36 (24.2%) |
| Fairly | 47 (31.5%) |
| Very much | 49 (32.9%) |

Equally, most of HIV clinicians in our sample (88.4%) considered that baseline CD4 lymphocyte screening is very or quite accessible (Table 4). On the contrary, the majority reported barriers or no access to baseline viral load testing (80%) and baseline genotype resistance tests (96%). 48% reported genotype testing as being not accessible at all. They reported delays of over 2 weeks in acquiring test results in all screening tests, with significant delays in viral load and genotypic resistance screening. Delays were primarily attributed to lack of reagents (65% viral load, 63.6% genotype resistance) and resources (15% viral load, 18.2% genotype resistance).

Table 4. HIV Specialists’ responses on testing accessibility.

| Accessibility of CD4 lymphocyte screening tests | Baseline Screening before Starting Treatment | Monitoring in Treatment Naive Patients | Monitoring in Treatment Experienced Patients |
|---|---|---|---|
| Very much | 16 (61.5%) | 4 (16.7%) | 4 (16%) |
| Fairly | 7 (26.9%) | 0 | 0 |
| Somewhat (after facing many systemic obstacles) | 2 (7.6%) | 15 (62.5%) | 14 (56%) |
| Not at all | 1 (4.0%) | 5 (20.8%) | 7 (28%) |

| Accessibility of viral load tests |  |
|---|---|
| Very much | 3 (12.0%) |
| Fairly | 2 (8.0%) |
| Somewhat (after facing many systemic obstacles) | 18 (72.0%) |
| Not at all | 2 (8.0%) |
Table 4. Cont.

|                              | Baseline Screening before Starting Treatment | Monitoring in Treatment Naïve Patients | Monitoring in Treatment Experienced Patients |
|------------------------------|---------------------------------------------|--------------------------------------|---------------------------------------------|
| Accessibility of genotype resistance tests |                                             |                                      |                                             |
| Very much                    | 1 (4.0%)                                    | 2 (8.3%)                             | 2 (8%)                                      |
| Fairly                       | 0                                           | 0                                    | 0                                           |
| Somewhat (after facing many systemic obstacles) | 12 (48.0%)                                  | 9 (37.5%)                           | 11 (44%)                                   |
| Not at all                   | 12 (48.0%)                                  | 13 (54.2%)                           | 12 (48%)                                   |
| Time span of receiving viral load results |                                             |                                      |                                             |
| 0–24 h                       | 0                                           | 0                                    | 0                                           |
| 25–72 h                      | 3 (12.5%)                                   | 2 (8.3%)                             | 2 (8.3%)                                   |
| 7–14 days                    | 4 (16.7%)                                   | 6 (25%)                              | 6 (25%)                                    |
| More than two weeks          | 17 (16.8%)                                  | 16 (66.7%)                           | 16 (66.7%)                                 |
| Time span of receiving genotypic resistance test results |                                             |                                      |                                             |
| 0–24 h                       | 0                                           | 0                                    | 0                                           |
| 25–72 h                      | 1 (4.3%)                                    | 1 (4.8%)                             | 1 (4.5%)                                   |
| 7–14 days                    | 0                                           | 0                                    | 0                                           |
| More than two weeks          | 22 (95.7%)                                  | 20 (95.2%)                           | 21 (95.5%)                                 |

During monitoring, HIV specialists reported the lowest accessibility for viral load and genotype resistance testing in treatment naïve patients. Treatment-experienced patients also suffered limited accessibility to viral load and genotype resistance testing for monitoring purposes as well as delays. These delays were considered particularly important by HIV clinicians both in treatment naïve (62.5% viral load testing and 81.8% genotypic resistance testing) and treatment-experienced patients (62.5% and 82.6%, respectively) and were mainly attributed to lack of reagents (61.9% and 68.2%, respectively, both treatment naïve and experienced patients) (Table 4).

Finally, more than 1 in 2 HIV clinicians reported having 0 to only 15% records of genotypic resistance data for PLWHIV diagnosed after 2015 (M = 15%, interquartile range = 30%).

4. Discussion

The aim of this study was to investigate barriers faced by PLWHIV in Greece with accessing laboratory tests for CD-4 lymphocytes, viral load, and genotype resistance. According to our findings, 17.6% of the PLWHIV sample did not undergo viral load testing (HIV RNA) within 2 weeks of their diagnosis, a finding that is statistically significantly correlated with year of diagnosis and place of residence. In addition, there is a marginally significant correlation between place of residence and time since the last HIV RNA viral load test, whereas 1 in 3 respondents reported perceiving them as not at all (11.4%) or somewhat (24.2%) accessible or available, after first having to overcome a series of systemic obstacles. Corresponding findings of the survey amongst HIV clinicians record a worse picture for access to laboratory testing, especially when it comes to viral load and genotypic resistance testing, compared to findings in the PLWHIV sample. This discrepancy could be attributed to the characteristics of the PLWHIV sample, all of whom are members of a strong Patient Association and exposed to or with access to patient advocacy.

Almost all study participants (99.3%) stated that they were receiving ART and 82.20% reported being aware of their viral load status. The latter indicator is higher than that reported previously. In the official European Center for Disease Control (ECDC) report
of 2018, Greece did not report any data on the percentage of patients with undetectable viral load [15]. Further, in a study by Vourli et al. (2018) [16] of the cascade of HIV care in 11 European countries, it was estimated that 73% of PLWHIV in these countries had successfully suppressed their viral load, with a significant variation between Greece (58.7%) and Denmark (86%). It was specifically mentioned that as early as 2016, Greece was faced with bureaucratic and financial challenges that affected access to laboratory testing. As a result, the country recorded the lowest rates, although the real proportion of people with undetectable viral load may be expected to be higher.

Our findings are in line with previously reported challenges and barriers in access to HIV-related health care services in other developed [17] or developing countries [18]. Although data on PLWHIV and health care accessibility in Greece, are lacking, there are some insights on such barriers for patients with chronic diseases. For instance, geographical disparities in access to cancer care have been reported from other studies conducted in Greek settings. Particularly, in Athanasakis et al., (2012) [6], cancer patients had to travel extensively to access appropriate care, if they resided outside of Athens, thus creating a two-tier cancer patient matrix. Such system shortcomings have been confirmed elsewhere [19–23]. In the HOPE studies [19–21], patients with rheumatoid arthritis [19], cancer [20], multiple sclerosis [21] and drug users with hepatitis C [22] reported critical barriers in accessing medicines, physical distance from providers and long waiting times for a medical appointment [7]. Similar barriers in access to health care were also reported for patients with beta-thalassemia in Greece, especially for those residing away from transfusion centers and have lower income [24]. Therefore, any challenges faced by people with HIV across their patient pathway, and in particular during screening for CD4 lymphocytes, viral load, and genotype resistance, should be viewed as part of wider reforms required in the NHS to ensure operational efficiency [25] and patient accessibility.

Yet, unlike these other chronic conditions, HIV is an infectious disease, where diagnosis, linkage to the healthcare system, early access to antiretroviral therapy, monitoring and screening according to the guidelines, constitutes a necessary condition for not only effectively managing the condition for the person living with it but also addressing a persistent challenge for public health [26]. Studies have demonstrated benefits of antiretroviral therapy initiation as soon as a person is diagnosed [27]; however, it should be accompanied by systematic and standardized laboratory testing confirmation [28]. It is, therefore, even more critical to remove all barriers in access to services across the pathway, if to ensure optimal individual and public health outcomes. Inability to access critical services, including laboratory testing, even by some PLWHIV, may still negatively impact public health outcomes and contribute to the health system not achieving the UNAIDS elimination goals [2].

Limitations

This study was conducted via email, therefore, PLWHIV with no registered email with Positive Voice did not have access to it. This may have introduced sampling bias, as it is likely that extremely vulnerable or marginalized PLWHIV with no access to the internet or no computer skills may not have been able to participate. Additionally, the purposive sampling approach may have inserted external validity biases; however, the authors believe that the current finding strongly represent the reality PLWHIV and HIV professionals are facing in Greece. All findings depict current trends.

5. Conclusions

This is the first study to quantify impact of barriers to access to laboratory testing for HIV amongst PLWHIV in Greece. Despite HIV management being a paradigm of efficient use of resources over the past decade [29], challenges with access to laboratory testing particularly for CD4 lymphocyte tests, viral load, and genotype resistance screening may critically undermine the ability of the health care system to achieve HIV elimination goals and impact on equity in access to care indicators for PLWHIV across the country.
Author Contributions: Conceptualization, K.S., G.T., C.G., N.D. and M.L.; methodology, K.S., G.T. and C.G.; formal analysis, G.T.; investigation, N.D., G.T. and M.L.; writing—original draft preparation, G.T. and C.G.; writing—review and editing, K.S., G.T., C.G., D.S.-P., N.D. and M.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded through an unrestricted research grant by GSK.

Institutional Review Board Statement: The study was approved by the Ethics Committee of the Health Policy Institute and was in line with the ethical standards set by the Declaration of Helsinki.

Informed Consent Statement: The study was approved by the Ethics Committee of the Health Policy Institute and was in line with the ethical standards set by the Declaration of Helsinki. Participation was voluntary, anonymized, and informed consent for participation was requested from all participants. This study was conducted by the Association of People Living with HIV without interference from the Health Policy Institute and did not include any intervention.

Data Availability Statement: The dataset used and analyzed during the current study is available from the corresponding author on reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hull, M.W.; Lima, V.D.; Hogg, R.S.; Harrigan, P.R.; Montaner, J.S. Epidemiology of treatment failure: A focus on recent trends. Curr. Opin. HIV AIDS 2019, 4, 467–473. [CrossRef] [PubMed]
2. Joint UN on HIV/AIDS. UNAIDS and Partners Launch Initiative to Improve HIV Diagnostics. Available online: http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/july/20140723dai (accessed on 15 July 2022).
3. Rivero, A.; Fernández, E.; Poveda, T.; Caylà, J.A. Burden of HIV infection, vulnerable populations and access barriers to healthcare. Enferm. Infect. Y Microbiol. Clin. 2018, 36, 3–9.
4. Pellowski, J.A. Barriers to care for rural people living with HIV: A review of domestic research and health care models. J. Assoc. Nurses AIDS Care 2013, 24, 422–437. [CrossRef] [PubMed]
5. NIAID. 10 Things to Know about HIV Suppression. 2020. Available online: https://www.niaid.nih.gov/diseases-conditions/10-things-know-about-hiv-suppression (accessed on 15 July 2022).
6. Athanasakis, K.; Souliotis, K.; Kyriopoulos, E.J.; Loukidou, E.; Kritikou, P.; Kyriopoulos, J. Inequalities in access to cancer treatment: An analysis of cross-regional patient mobility in Greece. Support Care Cancer 2012, 20, 455–460. [CrossRef] [PubMed]
7. Tsiakalakis, G.; Golna, C.; Dedes, N.; Papageorgiou, G.; Athanasakis, K.; Souliotis, K. HIV patient access to healthcare services in post-austerity era in Greece. Int. J. Hum. Rights Healthc. 2021, 14, 403–410. [CrossRef]
8. National Organization for Public Health. HIV/AIDS Surveillance in Greece. Data Reported through 31 December 2019. 2020. Available online: https://eody.gov.gr/wp-content/uploads/2018/12/epidimiologiko-deltio-hiv-2019.pdf (accessed on 15 July 2022).
9. National Organization for Public Health. Guidelines for Providing Antiretroviral Therapy (in Greek). 2018. Available online: https://eody.gov.gr/wp-content/uploads/2018/12/antiretroiki-agogi-11-05-2018.pdf (accessed on 15 July 2022).
10. European AIDS Clinical Society, EACS Guidelines. 2020. Available online: https://www.eacsociety.org/guidelines/eacs-guidelines.html (accessed on 15 July 2022).
11. National Organization for Public Health. HIV/AIDS Surveillance in Greece. 2018. Available online: https://eody.gov.gr/wp-content/uploads/2018/12/epidimiologiko-deltio-hiv-2018.pdf (accessed on 19 September 2022).
12. Hellenic Society for the Study and Control of AIDS. Infection Units and Treatment Centers for Care. Available online: https://www.aids.org.gr/%CE%BC%CE%BF%CE%BD%CE%AC%CE%B4%CE%B5%CF%82-%CE%BB%CE%BF%CE%B9%CE%BC%CF%8E%CE%BE%CE%B5%CF%89%CE%BD/ (accessed on 19 September 2022).
13. National Organization for Public Health. HIV/AIDS Surveillance in Greece. 2021. Available online: https://eody.gov.gr/wp-content/uploads/2020/07/epidimiologiko-deltio-hiv-2021.pdf (accessed on 19 September 2022).
14. National Organization for Public Health. Data on the Initiation of Antiretroviral Therapy in Greece, in Cases of HIV Infection. 2019. Available online: https://eody.gov.gr/wp-content/uploads/2020/07/%CE%91%CE%9D%CE%91%CE%A6%CE%9F%CE%A1%CE%91-%CE%98%CE%95%CE%A1%CE%91%CE%A0%CE%95%CE%99%CE%A9%CE%9D_2020_%CE%A4%CE%95%CE%9B%CE%99%CE%A9%CE%9F_07-09-21.pdf (accessed on 19 September 2022).
15. ECDC. Special Report. Continuum of HIV Care Monitoring Implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2018 Progress Report. 2018. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/HIV-continuum-of-care-monitoring-dublin-declaration-progress-report-2018.pdf (accessed on 15 July 2022).
16. Vourli, G.; Nikolopoulos, G.; Paparizos, V.; Skoutelis, A.; Metallidis, S.; Gargalianos, P.; Papadopoulos, A.; Chini, M.; Sipsas, N.V.; Psychogiou, M.; et al. HIV cascade of care in Greece: Useful insights from additional stages. PLoS ONE 2018, 13, e0207355. [CrossRef] [PubMed]
17. Washington, T.A.; D’Anna, L.; Meyer-Adams, N.; Malotte, C.K. From their voices: Barriers to HIV testing among black men who have sex with men remain. *Healthcare* **2015**, *3*, 933–947. [CrossRef] [PubMed]

18. Gesessew, H.; Lyon, P.; Ward, P.; Woldemichael, K.; Mwanri, L. Our Tradition Our Enemy: A Qualitative Study of Barriers to Women’s HIV Care in Jimma, Southwest Ethiopia. *Int. J. Environ. Res. Public Health* **2020**, *17*, 833. [CrossRef] [PubMed]

19. Souliotis, K.; Papageorgiou, M.; Politis, A.; Ioakeimidis, D.; Sidirooulos, P. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: The unseen impact of the fiscal crisis—The Health Outcomes Patient Environment (HOPE) study. *Rheumatol. Int.* **2014**, *34*, 25–33. [CrossRef] [PubMed]

20. Souliotis, K.; Agapidaki, E.; Papageorgiou, M. Healthcare access for cancer patients in the era of economic crisis. Results from the HOPE III study. *Forum Clin. Oncol.* **2015**, *6*, 7–11. [CrossRef]

21. Souliotis, K.; Alexopoulou, E.; Papageorgiou, M.; Politis, A.; Liatsi, P.; Contiades, X. Access to care for multiple sclerosis in times of economic crisis in Greece—The HOPE II study. *Int. J. Health Policy Manag.* **2016**, *5*, 83–89. [CrossRef] [PubMed]

22. Souliotis, K.; Agapidaki, E.; Papageorgiou, M.; Voudouri, N.; Contiades, X. Access to treatment for Hepatitis C among injection drug users: Results from the cross-sectional HOPE IV study. *Int. J. Equity Health* **2017**, *6*, 101. [CrossRef] [PubMed]

23. Souliotis, K.; Papadonikolaki, J.; Papageorgiou, M.; Economou, M. The impact of crisis on health and health care: Thoughts and data on the Greek case. *Arch. Hell Med.* **2018**, *35* (Suppl. S1), 9–16.

24. Souliotis, K.; Golna, C.; Nikolaidi, S.; Vatheia, G.; Hasurdjiev, S. Access to health care for patients with thalassaemia in Greece: A cross-sectional study. *East. Med. Health J.* **2020**, *26*, 1482–1492. [CrossRef] [PubMed]

25. Androutsou, L.; Geitona, M.; Yfantopoulos, J. Measuring Efficiency and Productivity across Hospitals in the Regional Health Authority of Thessaly in Greece. *J. Health Manag.* **2011**, *13*, 121–140. [CrossRef]

26. Rosen, S.; Fox, M.P. Retention in HIV care between testing and treatment in sub-Saharan Africa: A systematic review. *PLoS Med.* **2011**, *8*, e1001056. [CrossRef] [PubMed]

27. Cohen, M.S.; Chen, Y.Q.; McCauley, M. Prevention of HIV-1 infection with early antiretroviral therapy. *N. Engl. J. Med.* **2011**, *365*, 493–505. [CrossRef] [PubMed]

28. Bavinton, B.R.; Pinto, A.N.; Phanuphak, N.; Grinszteijn, B.; Prestage, G.P.; Zblotska-Manos, I.; Jin, F.; Fairley, C.K.; Moore, R.; Roth, N.; et al. Viral suppression and HIV transmission in serodiscordant male couples: An international, prospective, observational, cohort study. *Lancet HIV* **2018**, *5*, e438–e447. [CrossRef]

29. Athanasakis, K.; Naoum, V.; Naoum, P.; Nomikos, N.; Theodoratou, D.; Kyriopoulos, J. A 10-year economic analysis of HIV management in Greece: Evidence of efficient resource allocation. *Curr. Med. Res. Opin.* **2022**, *38*, 265–271. [CrossRef] [PubMed]